Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

First International Summit on Interventional Pharmacoeconomics

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Opening Session Panel Discussion

Varsha Gandhi, PhD, on Ibrutinib

May

Today In Oncology

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Related Videos

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Opening Session Panel Discussion

Varsha Gandhi, PhD, on Ibrutinib

FDA Approves Zenocutuzumab-zbco for Advanced, Unresectable, or Metastatic Cholangiocarcinoma

Long-Term Outcomes With Maintenance Rucaparib in Advanced Pancreatic Cancer With BRCA or PALB2 Pathogenic Variants

Tiragolumab Plus Atezolizumab and Chemotherapy in Advanced Nonsquamous NSCLC

Appendiceal Cancer: Serum Tumor Marker Levels May Guide Treatment in Patients Undergoing CRS

High YAP1 Expression Leads to Chemotherapy Resistance Relapse in Treated SCLC